LINC00022 acts as an oncogene in colorectal cancer progression via sponging miR-375-3p to regulate FOXF1 expression

Long noncoding RNA LINC01550 inhibits colorectal cancer malignancy by suppressing the Wnt/β-catenin signaling pathway

Colorectal cancer (CRC) is a common gastrointestinal malignancy. Long noncoding RNAs (lncRNAs) are associated with the progression of various cancers, including CRC. Herein, we explored the function of lncRNA LINC01550 in CRC. LINC01550 expression in CRC was analyzed using The Cancer Genome Atlas (TCGA). The diagnostic value of LINC01550 was evaluated using ROC curves. The relationship between clinicopathological variables and LINC01550 expression was explored, and its prognostic value was assessed using Kaplan-Meier and Cox regression analyses. The relationship between LINC01550 expression and immune cell infiltration was analyzed using CIBERSORT. Tumor-associated mutations and drug sensitivity were compared between high and low LINC01550 expression groups. The effects of LINC01550 overexpression on CRC cells were investigated using CCK-8, flow cytometry, wound healing, Transwell, qRT-PCR, and western blot assays. LINC01550 was downregulated in CRC tissues, and the low expression of LINC01550 was correlated with advanced stage and metastasis. CRC patients with low LINC01550 expression had poorer overall survival. LINC01550 expression was an independent risk factor for CRC prognosis. APC and TP53 mutations were more frequent in the low LINC01550 expression group, while the high LINC01550 expression group was significantly more sensitive to 5-fluorouracil, irinotecan, trametinib, gemcitabine, rapamycin, and XAV939. LINC01550 overexpression suppressed the proliferation, migration, invasion, and epithelial-mesenchymal transition of HCT-116 and HT-29 cells and promoted apoptosis. LINC01550 exerted these effects by inhibiting Wnt/β-catenin signaling. Our results suggest LINC01550 as a diagnostic and prognostic predictor in CRC that acts as a tumor suppressor and a potential therapeutic target.

Serum lncRNA LINC01535 as Biomarker of Diagnosis, Prognosis, and Disease Progression in Breast Cancer

BACKGROUND

Breast cancer has become the world's leading cancer, the leading killer of women's health, with a high mortality rate. With the development of medical technology, lncRNAs are widely used in the diagnosis and prognosis of various tumors, so finding new specific molecular markers and targets is the key to prolonging the survival time of breast cancer patients.

MATERIALS AND METHODS

The expressions of lncRNA LINC01535 and miR-214-3p in breast cancer were detected by quantitative real-time PCR (qRT-PCR). The diagnostic significance of LINC01535 in breast cancer was assessed by ROC curve. The prognostic value of LINC01535 was verified by Kaplan-Meier method. The regulation of low expression of LINC01535 on proliferation and other biological abilities of breast cancer cells was determined by CCK-8 and Transwell method. The luciferase activity report assays indicated the relationship between LINC01535 and miR-214-3p.

RESULTS

LINC01535 was elevated in breast cancer, which was negatively correlated with miR-214-3p, and miR-214-3p expression was decreased. LINC01535 proved to be promising in the diagnosis and prognosis of breast cancer. Low expression of LINC01535 targeting miR-214-3p had regulatory significance on tumor progression, lymph node metastasis and TNM stage.

CONCLUSION

Silencing LINC01535 inhibited the proliferation capacity, migration level and invasion of breast cancer cells in vitro. LINC01535 was likely to be the focus of continued attention as a diagnostic and prognosis marker for breast cancer in the future.

Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy

Anti-epidermal-growth-factor-receptor (EGFR) monoclonal antibodies (mAbs) are of great significance for RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients. However, the generation of primary and secondary resistance to anti-EGFR mAbs has become an important factor restricting its efficacy. Recent studies have revealed that non-coding RNAs (ncRNAs), especially long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and circular RNAs (circRNAs), are implicated in anti-EGFR antibodies resistance, affecting the sensitivity of CRC cells to Cetuximab and Panitumumab. This paper briefly reviewed the research advance of the expression, signaling network and functional mechanism of ncRNAs related to anti-EGFR mAbs resistance in CRC, as well as their relationship with clinical prognosis and the possibility of therapeutic targets. In addition, some ncRNAs that are involved in the regulation of signaling pathways or genes related to anti-EGFR resistance, but need to be further verified by resistance experiments were also included in this review, thereby providing more ideas and basis for ncRNAs as CRC prognostic markers and anti-EGFR therapy sensitizers. Video Abstract.